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Abstract 
Background: Surveys conducted in 1991–1992 in the Mbam Valley (Cameroon) revealed that onchocerciasis was 
highly endemic, with community microfilarial loads (CMFL) > 100 microfilariae/snip in some villages. Also in 1991–
1992, a survey of suspected cases of epilepsy (SCE) found 746 SCE using a questionnaire administered to individuals 
identified by key informants, with prevalences reaching 13.6% in some communities. From 1998, annual community‑
directed treatment with ivermectin (CDTI) was implemented to control onchocerciasis. In 2017, a door‑to‑door 
household survey was conducted in three of the villages visited in 1991–1992, using a standardized 5‑item epilepsy 
screening questionnaire.
Results: In 2017, a total of 2286 individuals living in 324 households were screened (582 in Bayomen, 553 in Ngongol 
and 1151 in Nyamongo) and 112 SCE were identified (4.9%). Neurologists examined 92 of these SCE and confirmed 
the diagnosis of epilepsy for 81 of them (3.5%). Between the surveys in 1991–1992 and 2017, the prevalence of SCE 
decreased from 13.6% to 2.5% in Bayomen (P = 0.001), from 8.7% to 6.6% in Ngongol (P = 0.205) and from 6.4% to 
5.4% in Nyamongo (P = 0.282). The median age of SCE shifted from 20 (IQR: 12–23) to 29 years (IQR: 18–33; P = 0.018) 
in Bayomen, from 16 (IQR: 12–21) to 26 years (IQR: 21–39; P < 0.001) in Ngongol and from 16 (IQR: 13–19) to 24 years 
(IQR: 19–32; P < 0.001) in Nyamongo. The proportions of SCE aged < 10, 10–19, 20–29 and ≥ 30 years shifted from 9.5, 
58.3, 25.0 and 7.1% in 1991–1992 to 2.7, 20.5, 39.3 and 37.5% in 2017, respectively.
Conclusions: SCE prevalence decreased overall between 1991–1992 and 2017. The age shift observed is probably 
due to a decrease in the number of new cases of epilepsy resulting from the dramatic reduction of Onchocerca volvu-
lus transmission after 19 years of CDTI.
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Background
In 2010 it was estimated that the number of people 
in the world with lifetime epilepsy (i.e. with a history 
of epilepsy, regardless of treatment or recent seizure 
activity) and with active epilepsy (i.e. who has had 
at least one epileptic seizure in the previous 5  years, 
regardless of antiepileptic drug treatment) were 68.8 
and 32.7  million, respectively [1]. However, important 
geographical disparities exist and an estimated 80% of 
people living with epilepsy (PWE) reside in low and 
middle-income countries [1, 2]. Moreover, estimated 
prevalences in Africa are amongst the highest observed 
worldwide, with 0.9% and 6.0% in sub-Saharan Africa 
and central Africa, respectively [3]. Incidence rates of 
epilepsy in sub-Saharan Africa range from 64 to 187 per 
100,000 person-years [4]. Evident causes including per-
inatal brain damage or parasitic diseases that are highly 
endemic in sub-Saharan Africa partly account for the 
high epilepsy burden endured by the region. Indeed, 
recent meta-analyses confirmed that neurocysticerco-
sis, toxocariasis, toxoplasmosis and cerebral malaria 
are closely associated with epilepsy, with common odds 
ratios of 2.7 (95% confidence interval, CI: 2.1–3.6), 1.69 
(95% CI: 1.42–2.01), 2.25 (95% CI: 1.27–3.9) and 4.68 
(95% CI: 2.52–5.70), respectively [5–8].
Onchocerca volvulus, the nematode causing oncho-
cerciasis that is transmitted from human to human by 
blackflies of the genus Simulium, has also been asso-
ciated with epilepsy as early as 1938 [9]. More recent 
studies and meta-analyses have confirmed that this 
association is significant (pooled odds ratio: 2.49, 95% 
CI: 1.60–3.86) [10–14], though the causal relationship 
and the pathological mechanisms involved are yet to be 
demonstrated and elucidated.
During the past 25  years, all African onchocer-
ciasis-endemic countries have established national 
control programmes based on annual mass community-
directed treatment with ivermectin (CDTI). Recent 
observations in the Democratic Republic of Congo 
(DRC) and northern Uganda suggest that onchocerci-
asis control through CDTI (plus vector control in the 
case of Uganda) may decrease the incidence of epilepsy 
[15–17]. The benefit of CDTI may result from the pri-
mary prevention of new cases of O. volvulus infection 
or the reduction in microfilarial density during child-
hood, even though an improvement in the frequency or 
severity of seizures after ivermectin treatment has also 
been suggested [18].
This study aimed at assessing the impact of repeated 
CDTI campaigns on (i) epilepsy prevalence and (ii) age 
distribution of suspected cases of epilepsy (SCE), in 
three villages of the Mbam Valley, Cameroon. These vil-
lages are located in an onchocerciasis-endemic area 
that we initially surveyed in 1991–1992, and in 2017 
after a 25-year interval, including 19  years of CDTI 
implementation.
Methods
Study sites and procedures for the 1991–1992 surveys
Parasitological surveys were conducted in 25 villages of 
the Mbam Valley (“Mbam et Kim” and “Mbam et Inou-
bou” divisions, Centre Region, Cameroon) between 1991 
and 1992, to measure the levels of infection with O. vol-
vulus [19]. In view of the concerns about epilepsy raised 
by the local population, 14 villages were selected for 
assessing the number of SCE. The local population had a 
fairly good knowledge of the condition [20], including the 
two main types of epilepsy: generalized tonic-clonic sei-
zures (“persons who fall”) and absence seizures. For each 
village, after sensitization of the community leaders, the 
village chiefs gathered at one location all those who were 
seen in the village as having epilepsy. Where a subject 
did not wish to come to the meeting point, they were vis-
ited at home. After recording his/her full name, sex and 
age, each subject was questioned separately by a physi-
cian and a nurse, together with close relatives who had 
witnessed one or more of the epileptic episodes. Indi-
viduals were considered to be suspected of having epi-
lepsy if one of the following situations occurred at least 
twice without obvious cause: (i) fell to the ground with 
loss of consciousness; (ii) had shaking movements of the 
arms or legs without control; or (iii) seemed to be absent 
and did not answer questions asked by relatives. Careful 
questioning on the frequency and the circumstances of 
the seizures, the age at first seizure, and the anti-epileptic 
drugs taken allowed to distinguish SCE from other con-
ditions such as isolated seizures or febrile convulsions. In 
most cases, SCE presented with typical symptoms of gen-
eralized tonic-clonic seizures or absence seizures. SCE 
were not re-examined by a neurologist to confirm the 
diagnosis of epilepsy. To calculate prevalences, the total 
number of people living in each village was extrapolated 
from the second general population and housing census 
of 1987, for which data by village was available, and a 
growth rate of 2.3% per year was applied.
Study sites and procedures for the 2017 survey
Three of the 14 communities surveyed in 1991–1992 were 
selected to be revisited in 2017, namely Bayomen (initial 
proportion of SCE: 13.6%, 15/110), Nyamongo (6.4%, 
40/627) and Ngongol (8.7%, 28/323). The selection was 
done using two criteria: (i) the initial (1991–1992) preva-
lence of SCE had to be high to ensure sufficient statistical 
power while comparing to 2017 data; and (ii) they had to 
be fairly well separated from neighboring communities to 
prevent confusion during the population census in 2017. 
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These villages are located in an area of a forest-savanna 
mosaic, 100  km north of Yaoundé (Cameroon’s capital 
city), and less than 2  km from the Mbam river with its 
numerous rapids suitable for Simulium breeding (Fig. 1). 
In 1991–1992, the community microfilarial load (CMFL, 
defined as the geometric mean of the individual micro-
filarial densities per skin snip in those aged ≥ 20  years, 
calculated after having added 1 to each density to include 
zero counts), was 88.4 microfilariae per skin snip (mf/ss) 
in Ngongol and 46.8 mf/ss in Nyamongo. The CMFL was 
not measured in Bayomen, but was certainly also very 
high. The principal activity of the people in this region is 
agriculture and to a lesser extent fishing and sand mining 
in the river. From 1998 onwards, all villages in the study 
area benefitted from annual CDTI developed by the Afri-
can Programme for Onchocerciasis Control (APOC) but 
no vector control activity was ever conducted in the area. 
Additionally, the study area appears to be either free or 
subjected to a marginal impact of other epileptogenic 
parasitic diseases (i.e. cysticercosis, paragonimiasis, tryp-
anosomiasis) [21–23].
A door-to-door household epilepsy survey was con-
ducted in the three selected villages in July 2017. A 
community questionnaire was administered to the key 
informants (village chiefs and secretaries) to obtain 
information on the village and its evolution over the 
last 25  years. The community health workers and/or 
ivermectin distributors who were trusted by the local 
population guided the investigators throughout the vil-
lage and served as interpreters when necessary. Inves-
tigators provided adequate information about the study 
and obtained written consent from the household head 
before collecting demographic information (age and sex) 
for all the household members, and administering a vali-
dated 5-item questionnaire for epilepsy screening (see 
Additional file 1) [24]. The items were: (i) history of loss 
of consciousness and/or loss of bladder control and/or 
drooling; (ii) history of absence or sudden lapse of con-
sciousness during a short period; (iii) history of sudden 
unintentional clonic movements or muscular jerks of 
arms and/or legs (convulsions) that stopped within min-
utes; (iv) history of sudden and brief bodily sensations, 
seeing or hearing things that are not there, or smelling 
strange odors; and (v) having been told that he/she had 
epilepsy or had experienced 2 epileptic episodes. SCE 
were asked whether they had already taken ivermectin 
Fig. 1 Map of the study area. Crude prevalence estimates are based on the suspected cases of epilepsy. The map was created CBC by using ArcGIS 
v.10.3.1. (ESRI 2018). The basemap layer was retrieved from OpenStreetMap and contributors, CC‑BY‑SA (http://www.opens treet map.org)
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and examined for the presence of cutaneous signs of 
onchocerciasis. Data related to the place of birth and the 
occupation of the household head, as well as the history 
of death due to epilepsy within the household, was also 
collected from the household head. Indigenous house-
holds were defined as those in which the household head 
was born in the village.
Case definitions
People who screened positive for one or more questions 
in the 5-item questionnaire (including those taking anti-
epileptic medication) were recorded as SCE and evalu-
ated by a neurologist using a more detailed questionnaire. 
A SCE was considered as a PWE if there was a history 
of at least two unprovoked seizures separated by 24 h or 
more, therefore excluding seizures related to acute events 
such as fever, trauma, substance abuse or withdrawal 
[25]. The possible epilepsy (PE) group included PWE and 
SCE who could not be examined by the study neurolo-
gists, and therefore for whom diagnosis of epilepsy was 
not ruled out.
Serologic assessment of the transmission of O. volvulus 
in 2017
Ongoing onchocerciasis transmission in the villages was 
assessed in children aged 7–10 years using the SD Bioline 
Onchocerciasis Ov16 IgG4 rapid diagnostic test (RDT) 
(Standard Diagnostics, Gyeonggido, South Korea) for 
anti-Onchocerca antibodies.
Statistical analyses
Categorical variables were summarized using percent-
ages and compared using Chi-square tests. Continuous 
variables were summarized using median and interquar-
tile ranges (IQR) and compared using the non-paramet-
ric Wilcoxon-Mann-Whitney test.
Potential predictors for epilepsy were investigated 
using bivariate mixed model analysis. All variables with 
a P-value of < 0.20 in the bivariate analysis were entered 
into a multivariable logistic mixed model analysis with a 
backward approach. Multivariable models systematically 
included gender, village, and age (≤ 15, 15–30, > 30 years) 
as independent variables. A random effect was set at the 
household level and allowed for evaluation of the intra-
class correlation coefficient. Adjusted odds ratios (aORs) 
were calculated with 95% confidence intervals (95% CI). 
Crude incidence rates were approached by using the 
number of SCE with onset of epilepsy in 1986–1990 or 
2012–2016 (n) divided by the estimated number of peo-
ple at risk during the same 5-year period (N). A 5-year 
period was used due to the small number of new events 
occurring in a 1-year time period. Assuming that the 
population in the villages was relatively stable during the 
two 5-year periods, we assumed that the populations at 
the end of these periods were that estimated for 1991 
(from data of the 1987 national population census), and 
that recorded in 2017 (during the survey), respectively. 
The number of people with onset of epilepsy prior to 
1986 or 2012 and the number of people for whom the 
year of onset of epilepsy was not known were subtracted 
from these populations to obtain the denominators on 
which the incidence rates were calculated. We considered 
that the death and migrations of new cases of epilepsy 
during the 5-year period would have a minimal effect on 
the incidence. The incidence of epilepsy was presented 
as cases per 100,000 person-years (PY). The significance 
level was set at P < 0.05. All P-values were two-sided. All 
analyses were performed using R software, v.3.4.2, and 
Stata v.13.1 software (StataCorp, College Station, USA).
Standardization method
Crude prevalences were compared using Chi-square 
tests. Standardized prevalences were calculated using 
the sex and age structure of the population in the vil-
lages (age groups: 0–4, 5–9, 10–14, 15–19, 20–29, 30–39, 
> 40  years). In the 1991–1992 survey, the numbers of 
individuals in a given category were estimated using the 
total population in the village and the age and sex struc-
ture of the rural population recorded during the 1987 
national census in the districts where the study villages 
are located. In order to enable a comparison of the preva-
lences between the surveys in 1991–1992 and 2017, a 
direct standardization was then performed by weighting 
the estimated SCE prevalences by sex and age group of 
1991 using the age and sex structure of the population 
surveyed in 2017 [26].
Sensitivity analysis
The primary analyses were conducted on the total num-
ber of PWE identified in 2017. Sensitivity analysis was 
performed on the SCE and the PE cases. In addition, the 
survey conducted in 2017 revealed that significant immi-
gration occurred into these villages between the sur-
veys in 1991–1992 and 2017 (see “Results”). The CMFL 
in 1991 in the study villages were extremely high (see 
above), and subjects who arrived in these communities 
between the two surveys most probably came from areas 
with lower exposure to O. volvulus, although we lack 
information on their exact origin. Thus, this immigration 
might have led to an artificial reduction in the CMFL in 
the villages and, should high microfilarial densities cause 
epilepsy, to an artificial reduction in the SCE prevalence 
in 2017. To prevent the risk of an over-detection of a 
decrease in prevalence between 1991 and 2017, we con-
ducted a sensitivity analysis restricted to the members of 
the indigenous households.
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Results
Study population
A total of 324 households were screened in 2017, con-
sisting of 2286 individuals: 582 (88 households) in Bayo-
men; 553 (86 households) in Ngongol; and 1151 (150 
households) in Nyamongo. Individuals’ and household 
characteristics are presented in Table 1. There were 1148 
women (50.2%) in the study population and the median 
age was 18 years (interquartile range, IQR: 7–33).
The proportion of indigenous households varied from 
28.4% in Bayomen to 40.7% in Ngongol and 75.3% in 
Nyamongo. The proportion of households that had 
Table 1 Characteristics of individuals and households surveyed in 2017. Indigenous households were defined as those in which the 
household head was born in the village
a Data missing
b For PWE only
Abbreviations: SCE, suspected case of epilepsy; PWE, persons living with epilepsy; PE, persons with possible epilepsy (PWE and SCE who could not be examined by a 
neurologist); NS, nodding seizures
Characteristic Total Bayomen Ngongol Nyamongo
Individuals’ characteristics n = 2286 n = 582 n = 553 n = 1151
Age (years), median (IQR) 18 (7–33) 15 (6–32) 20 (8–35) 18 (8–33)
Female, n (%) 1148 (50.2) 306 (52.6) 261 (47.2) 581 (50.5)
Male, n (%) 1138 (49.8) 276 (47.2) 292 (52.8) 570 (49.5)
Household characteristics n = 324 n = 88 n = 86 n = 150
Number of people per household, median (IQR) 6 (4–9) 6 (4–9) 6 (4–8) 7 (5–10)
Number of households whose head’s occupation is agriculture, n (%) 278 (85.8) 70 (79.6) 73 (84.9) 135 (90.0)
Number of indigenous households, n (%) 173 (53.4) 25 (28.4) 35 (40.7) 113 (75.3)
For migrants, year of immigration, median (IQR) 2008 (1997–2014)a 2012 (2002–2015) 2002 (1987–2013)a 2003 (1992–2013)a
Number of households with
 1 SCE, n (%) 59 (18.2) 12 (13.6) 23 (26.7) 24 (16.0)
 2 SCE, n (%) 14 (4.3) 2 (2.3) 4 (4.7) 8 (5.3)
 3 or more SCE, n (%) 7 (2.2) 1 (1.1) 1 (1.2) 5 (3.3)
Number of households with history of death from epilepsy, n (%) 52 (16.1)a 12 (13.6) 16 (18.6)a 24 (16.0)a
 Year of death, median (IQR) 2007 (2000–2011) 2005 (1999–2009) 2009 (1999–2013) 2007 (2001–2010)
 Age at death (years), median (IQR) 20 (15–27) 19 (14–28) 21 (15–27) 20 (17–29)
Number of SCE, PWE and PE
In the whole population
 SCE, n (%) 112 (4.9) 19 (3.3) 34 (6.2) 59 (5.1)
 PWE, n (%) 81 (3.5) 15 (2.6) 24 (4.3) 42 (3.7)
 PE, n (%) 101 (4.4) 17 (2.9) 29 (5.2) 55 (4.8)
In the indigenous population
 SCE, n (%) 79 (5.9) 14 (6.7) 15 (6.5) 50 (5.5)
 PWE, n (%) 58 (4.3) 11 (5.3) 10 (4.3) 37 (4.1)
 PE, n (%) 71 (5.3) 13 (6.3) 12 (5.2) 46 (5.1)
Characteristics of SCE, PWE and PE
Age, median (IQR)
 SCE 26 (20–34) 29 (18–33) 26 (21–39) 24 (19–32)
 PWE 24 (20–32) 26 (18–33) 24 (20–31) 24 (20–32)
 PE 24 (20–32) 29 (21–33) 23 (20–28) 24 (19–30)
 Not epilepsy patient 46 (20–70)
Age at onset (years), median (IQR)b 12 (10–14)a 11 (9–13) 11 (9–13) 13 (10–15)a
Year of onset, median (IQR)b 2004 (1996–2010)a 2002 (1995–2011) 2003 (1994–2009) 2006 (1996–2010)a
Type of seizures
 Only NS, n (%)b 2 (2.5) 0 0 2 (4.8)
 NS and other types of seizures, n (%)b 21 (25.9) 3 (20.0) 9 (37.5) 9 (21.4)
 Other types of seizures, n (%)b 58 (71.6) 12 (80.0) 15 (62.5) 31 (73.8)
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moved in from other locations was particularly high in 
Bayomen where the median year of arrival of the indi-
viduals recorded in 2017 was 2012 (IQR: 2002–2015). 
The median age of the indigenous and non-indigenous 
residents was 18 (IQR: 7–35) and 17  years (IQR: 7–32) 
(P = 0.059), respectively. Agriculture was the main 
declared occupation for 85.8% (n = 278) of the household 
heads, and each household housed a median of 6 people 
(IQR: 4–9).
Village data
In all three villages, CDTI was first implemented in 1998. 
In Bayomen, two people including the village chief and 
a certified nurse handled the drug distribution, with no 
interruption since 1998 (last distribution in June 2017). 
There was only one community distributor in Ngongol 
who reported no interruption in CDTI in the last 15 years 
(last distribution in July 2017), and two distributors in 
Nyamongo where the supply of ivermectin was repeat-
edly insufficient to ensure a good population coverage 
(last distribution in June 2016). There were no health 
centers in Bayomen and Ngongol. Antiepileptic drugs 
(AED) (phenobarbital and carbamazepine) were available 
in a private drug store in Bayomen, whereas in the other 
villages inhabitants had to buy AED in the city of Bafia 
(see Fig.  1). In Bayomen, the key informant reported a 
massive arrival of inhabitants who moved in from other 
regions of Cameroon, whereas there were only a few 
departures from Ngongol since 2015 without arrivals and 
no major change in Nyamongo.
Suspected cases of epilepsy
In 2017, the 5-item questionnaire administered to the 
household heads (and the subjects if they were present) 
allowed the identification of 112 SCE (prevalence of 
SCE: 4.9%). Among those who were later confirmed to 
be PWE, 71 (87.7%) had a positive answer to question 
1, 33 (40.7%) to question 2, 65 (80.3%) to question 3, 10 
(12.4%) to question 4 and 72 (88.9%) to question 5 [“have 
you (he/she) been told that you (he/she) had epilepsy or 
had had 2 epileptic episodes?”]. In contrast, only 3 of the 
11 SCE (27.3%) for whom the diagnosis of epilepsy was 
refuted had a positive answer to this question 5. Fifty-two 
households (16.1%) had already lost one member, likely 
due to epilepsy (suspected), at a median age of 20 years 
(IQR: 15–27) (Table 1).
Confirmed cases of active epilepsy
In 2017, 92 of the 112 SCE could be examined by neu-
rologists, who confirmed the diagnosis of active epi-
lepsy in 81 of them (positive predictive value: 88.0%) 
(Fig. 2). Therefore, the prevalence of confirmed epilepsy 
was 3.5%. Twenty SCE could not be examined by neu-
rologists, mainly because they were absent during the 
survey (i.e. the questionnaire was administered only to 
the household head), raising the prevalence of possible 
epilepsy to 4.4% (n = 101). The median age of unexam-
ined SCE was 25  years (IQR: 20–30), 11 (55%) were 
males, and 16 (80%) had provided a positive answer to 
question 5.
In univariate analysis, factors associated with the 
PWE status were age, living in an indigenous house-
hold, and a history of death due to epilepsy within the 
household (Table  2). In multivariable mixed model 
analysis, and using the individuals aged < 15  years as 
the reference group, age remained strongly associated 
with PWE status, with aOR = 11.6 (95% CI: 5.4–25.4; 
P < 0.001) for the 15–30 age group and aOR = 3.9 (95% 
CI: 1.7–9.0; P = 0.002) for the > 30 age group. Indig-
enous households remained associated with a higher 
risk (aOR = 2.1; 95% CI: 1.1–4.2; P = 0.026), but hav-
ing a household history of death due to epilepsy was no 
longer significant. The results obtained as part of the 
sensitivity analysis were similar, whatever the popula-
tions of epilepsy cases considered (SCE, PWE or PE 
cases) (Table 3). The random effect associated with the 
household was significant (P < 0.001), with an intra-
class correlation coefficient equal to 23%.
Comparison of the prevalences measured in 1991–1992 
and 2017
The crude prevalence of SCE in the three villages 
decreased from 7.8% in 1991–1992 to 4.9% in 2017 
(P < 0.001). When the villages were taken separately, 
the decrease was significant in Bayomen (from 13.6% 
to 3.3%; P = 0.001), but not in Ngongol (from 8.7% to 
6.2%; P = 0.205) or in Nyamongo (from 6.4% to 5.1%; 
P = 0.282) (Fig. 3). When the analysis was restricted to 
indigenous households, the crude prevalences of SCE in 
2017 were 6.7% (14/208) in Bayomen, 6.5% (15/232) in 
Ngongol and 5.5% (50/905) in Nyamongo. Considering 
that most of the SCE in 1991–1992 lived in indigenous 
households, the crude prevalence in this sub-popula-
tion significantly decreased in Bayomen (P = 0.042) but 
not in Ngongol (P = 0.338) or Nyamongo (P = 0.484). 
When the SCE prevalence recorded in 1991–1992 was 
standardized on the age and sex structure of the pop-
ulation surveyed in 2017, standardized prevalences 
of 12.9% in Bayomen, 9.7% in Ngongol and 7.6% in 
Nyamongo were obtained. Comparisons of the preva-
lences standardized on the same sex- and age-structure 
show that they decreased significantly between the 
surveys in 1991–1992 and 2017 in the three villages 
(P < 0.001, P = 0.034 and P = 0.017, respectively).
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Fig. 2 Study flowchart. *SCE, suspected case of epilepsy; **PWE, person with epilepsy
Table 2 Factors associated with epileptic status in the univariate analyses
PWE SCE Possible epilepsy
OR 95% CI P OR 95% CI P OR 95% CI P
Male sex (ref: female) 1.03 0.65–1.63 0.893 1.00 0.67–1.48 0.990 1.06 0.70–1.61 0.766
Village
 Bayomen ref ref ref
 Ngongol 1.95 0.90–4.25 0.091 2.18 1.10–4.30 0.025 2.12 1.03–4.37 0.042
 Nyamongo 1.36 0.67–2.77 0.396 1.59 0.85–2.96 0.147 1.69 0.88–3.26 0.116
Age
 < 15 years ref ref ref
 15–30 years 12.20 5.64–26.40 <0.0001 9.71 5.22–18.05 <0.0001 11.29 5.79–22.01 <0.0001
 > 30 years 4.40 1.92–10.10 <0.0001 4.07 2.10–7.91 <0.0001 3.78 1.83–7.82 <0.0001
Lives in an indigenous household (ref: no) 1.78 1.00–3.18 0.049 1.71 1.05–2.81 0.032 1.69 1.01–2.84 0.046
Household history of death from epilepsy (ref: no) 1.93 1.00–3.70 0.050 2.30 1.33–3.96 0.003 1.83 1.01–3.30 0.047
Household head occupation: agriculture (ref: other) 1.98 0.72–5.44 0.184 1.32 0.61–2.84 0.481 1.73 0.72–4.13 0.218
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Shift in the age distribution of SCE between the surveys 
in 1991–1992 and 2017
Considering the three villages together, the median age 
of SCE increased from 16  years in 1991 (IQR: 13–21) 
to 26  years in 2017 (IQR: 20–34; P < 0.001) (Table  4). 
At the village level, SCE age increased from 20 (IQR: 
12–23) to 29  years (IQR: 18–33; P = 0.018) in Bayo-
men, from 16 (IQR: 12–21) to 26  years (IQR: 21–39; 
P < 0.001) in Ngongol and from 16 (IQR: 13–19) to 
24 years (IQR: 19–32; P < 0.001) in Nyamongo (Fig. 4). 
In 1991–1992, 49 (58.3%) of the SCE were 10–19 years-
old (prevalence of 22.3%), whereas 21 (25.0%) were 
20–29 years-old (prevalence of 16.3%). In 2017, only 23 
(20.5%) of the SCE were 10–19  years-old (prevalence 
of 4.9%), whereas the majority (n = 44; 39.3%) were 
20–29 years-old (prevalence of 11.6%) (Table 4).
The median age at first seizure of the PWE recorded 
in 2017 was 12  years (IQR: 10–14) and was similar in 
the three villages. This median age at first seizure was 
similar in the 1991–1992 survey (12 years, IQR: 8–15; 
P = 0.294). Those surveyed in 2017 had been living for 
a longer time with epilepsy (12.5  years, IQR: 7–21) 
as compared with 1991–1992 (5  years, IQR 2–7.5; 
P < 0.001).
Incidence rates
Crude incidence rates were estimated to be roughly 802 
SCE per 100,000 PY for the 1985–1990 period (n = 41 
incident cases, N = 1060 at risk) as compared to 146 
SCE per 100,000 PY for the 2012–2016 period (n = 16 
incident cases including 2 in Bayomen, 4 in Ngongol 
and 10 in Nyamongo, among a total of 2190 at risk).
Results of the Ov16 rapid diagnostic tests in children
A total of 307 children aged 7–10 years were examined 
(121 in Bayomen, 85 in Ngongol and 101 in Nyamongo). 
The proportions of Ov16-positive children did not dif-
fer significantly between the three villages (55.4, 42.4 
and 46.5%, respectively; P = 0.156). The values tended 
to decrease with age (54.2, 51.9, 46.8 and 41.0% in chil-
dren aged 7, 8, 9 and 10 years, respectively), the differ-
ence being not significant (P = 0.309).
Table 3 Factors associated with epileptic status in the multivariable mixed model analysis (n = 2246)
Abbreviations: PWE, person living with epilepsy; SCE, suspected case of epilepsy; OR, odds ratio; aOR, adjusted OR; ref, reference
P aOR 95% CI P aOR 95% CI P
Male sex (ref: female) 1.13 0.69–1.84 0.622 1.09 0.72–1.64 0.691 1.15 0.74–1.79 0.523
Village
 Bayomen ref ref ref
 Ngongol 1.51 0.66–3.44 0.325 1.66 0.83–3.33 0.151 1.70 0.79–3.64 0.174
 Nyamongo 0.85 0.39–1.87 0.688 1.09 0.56–2.10 0.802 1.18 0.58–2.43 0.647
Age
 < 15 years ref ref ref
 15–30 years 11.64 5.35–25.36 <0.0001 9.01 4.84–16.15 <0.0001 10.70 5.46–20.96 <0.0001
 > 30 years 3.85 1.66–8.98 0.002 3.53 1.80–6.92 <0.0001 3.37 1.61–7.05 0.001
Lives in an indigenous 
household (ref: no)
2.14 1.09–4.19 0.026 1.91 1.10–3.30 0.021 1.78 0.98–3.22 0.057
Household history of 
death from epilepsy 
(ref: no)
1.74 0.89–3.37 0.104 2.03 1.19–3.47 0.009 1.63 0.89–2.96 0.112
Fig. 3 Variation in crude prevalences of SCE between 1991–1992 
(dark grey) and 2017 (light grey). Abbreviations: SCE, suspected case of 
epilepsy; NS, no significant difference
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Discussion
Our study is, to our knowledge, the first study that has 
(i) permitted comparison of the burden of epilepsy in the 
same communities in a hyperendemic onchocerciasis 
area, before and after repeated rounds of CDTI (19 years 
since first implementation); (ii) used epilepsy screening 
tools that are very similar to those used before imple-
mentation of CDTI; and (iii) employed standardization 
techniques to ensure more accurate comparisons. Our 
study therefore brings new evidence to support the idea 
that CDTI has a significant impact on epilepsy burden.
Both crude and standardized epilepsy prevalences 
significantly decreased overall between the surveys in 
1991–1992 and 2017. It could be argued that, with an 
estimation of 70% of survival at 10  years among people 
with epilepsy [27], and with the follow-up of 25 years in 
our study, more than half of the people living with epi-
lepsy in 1991–1992 had died, therefore not contributing 
any more to the prevalences observed in 2017. Neverthe-
less, the prevalence of any endemic disease remains stable 
under the hypothesis that the incidence rate is coun-
terbalanced by the mortality rate. The decrease in SCE 
prevalence that we observed can thus be either related to 
a rise in the mortality rate (which would imply worsen-
ing of the care of people living with epilepsy, seemingly 
unlikely given the trends towards gaining better access 
to medications and health facilities) or to a decrease 
in incidence. The age of onset of epilepsy remained 
unchanged between 1991–1992 and 2017. Meanwhile, 
PWE surveyed in 2017 were older, with a higher dura-
tion of disease, as compared with 1991–1992. Altogether 
these results imply a greater survival of PWE in 2017 and 
fewer new cases of epilepsy in recent years. It is therefore 
unlikely that there was a rise in mortality among PWE in 
our study population. Nevertheless, the incidence figures 
should be interpreted cautiously even though the crude 
rates show a drastic decrease after 25  years. Altogether 
our results highlight that the age shift in the PWE popu-
lation can be interpreted as a cohort effect.
The difference in prevalence was striking in Bayomen, 
which was the only village where the decrease in the 
crude prevalence between 1991–1992 and 2017 was sta-
tistically significant. This difference between Bayomen 
and the two other villages might be due to (i) a higher 
CDTI coverage in Bayomen, where the village chief was 
also the ivermectin community distributor, whereas there 
were complaints in Ngongol and Nyamongo over short-
ages of ivermectin and suboptimal therapeutic coverage; 
(ii) an under- or overestimation of the SCE prevalences 
in 1991–1992; and/or (iii) the much higher immigration 
rate in Bayomen, leading to an artificial overestimation of 
the decrease in the prevalence in the village. Even if it is 
Table 4 Comparison of the age characteristics of the epilepsy cases in 1991–1992 and 2017
a Estimated number of people per age group (< 10, 10–19, 20–29 and ≥ 30 years) were obtained by applying the age structure of districts from the 1987 census
b 8 missing data
Abbreviation: na, not available
1991–1992 2017
SCE SCE P PWE P
Age (years), median (IQR) 16 (13–21) 26 (20–34) <0.001 24 (20–32) <0.001
Age group
 < 10 years, n (%) 8 (9.5) 3 (2.7) 1 (1.2)
 10–19 years, n (%) 49 (58.3) 23 (20.5) 18 (22.2)
 20–29 years, n (%) 21 (25.0) 44 (39.3) 34 (42.0)
 ≥ 30 years, n (%) 6 (7.1) 42 (37.5) 28 (34.6)
Crude age‑specific  prevalencea <0.001 <0.001
 < 10 years, (%) 2.5 0.4 0.1
 10–19 years, (%) 22.3 4.9 3.8
 20–29 years, (%) 16.3 11.6 9.0
 ≥ 30 years, (%) 1.6 6.0 4.0
Age at onset (years), median (IQR) 12 (8–15)b na 12 (10–14)c 0.294
Age group at onset
 < 10 years, n (%) 21 (25.0) 19 (24.4)
 10–19 years, n (%) 49 (58.3) 57 (73.1)
 20–29 years, n (%) 5 (6.0) 1 (1.3)
 ≥ 30 years, n (%) 1 (1.2) 1 (1.3)
Years since onset of epilepsy, median (IQR) 5 (2.0–7.5)b na 12.5 (7–21)b <0.001
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known that the sensitivity of the Ov16 RDT is lower than 
that of the Ov16 ELISA [28], the finding of a similar high 
prevalence of Ov16 antibodies in children 7–10  years-
old in the three villages suggests a similar high degree 
of ongoing O. volvulus transmission, which could partly 
be due to programmatic reasons, including suboptimal 
ivermectin supply and poor monitoring. The observation 
that in 2017 the proportions of SCE and PWE in the total 
population of Bayomen (3.3 and 2.6%, respectively) were 
fairly low in comparison to those in the population of the 
indigenous households (6.7 and 5.3%, respectively) makes 
the latter hypothesis likely. The rapid increase in the size 
of Bayomen due to migration (population: 110 in 1991–
1992 and 582 in 2017; to be compared with 323 and 553, 
respectively, in Ngongol; and to 627 and 1151, respec-
tively, in Nyamongo) might also have led to a decrease in 
the individual exposure to blackflies (in the “vector-to-
host ratio” [29]), and thus a slower increase in the O. vol-
vulus microfilarial densities in the population, including 
the children.
Previous surveys conducted in onchocerciasis endemic 
areas in Africa before the introduction of CDTI showed 
that epilepsy prevalences were highest in the popula-
tion aged 10–20  years (median age range 11–20  years; 
proportion in age group: 48.1–67.2% of all epileptic 
patients) [30–36]. Interestingly, two cross-sectional 
surveys conducted in Nigeria and Cameroon, in which 
several years of CDTI had been ongoing, showed that 
Fig. 4 Age shift of the cohort of people living with epilepsy between 1991–1992 and 2017
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epilepsy prevalences were higher in the 20–29 years age 
group [37, 38]. These observations suggest that CDTI 
may reduce the incidence of epilepsy, although no base-
line data were available. A case–control study conducted 
in onchocerciasis-endemic regions Democratic Repub-
lic of Congo (DRC) suggested that among people show-
ing signs of onchocerciasis, those who took ivermectin 
were less likely to develop epilepsy than those who did 
not (OR = 0.52; 95% CI 0.28–0.98) [15]. To date, the 
exact mechanism driving the ascertained association 
between mass distribution of ivermectin and the decline 
in the prevalence of epilepsy remains to be elucidated. A 
recent study by our team showed a temporal relationship 
between onchocerciasis acquisition and development of 
epilepsy [39] suggesting that the action of ivermectin is 
likely mediated by its impact on Onchocerca volvulus, 
although it is also effective on other parasites. In studies 
performed before the introduction of ivermectin, micro-
filariae have been occasionally observed in cerebrospinal 
fluid [40, 41]. Therefore, the parasite itself may cause sei-
zures or they may be caused by a more complex mecha-
nism linked to a previous transit of parasites within the 
host immune system, including the hypothesis of the 
induction of a neurotoxic auto-immune response.
One limitation to our study resides in the lack of com-
plete data on the present intensity of infection with O. 
volvulus, and on the therapeutic coverage achieved dur-
ing the CDTI organized in the communities. However, 
the results of the examination of children by the Ov16 
RDT demonstrate that transmission of onchocerciasis 
is ongoing at fairly high levels, thus corroborating the 
results of a parasitological survey conducted in 2015 in 
four villages of the study area, including Ngongol [42]. 
In the latter village, the prevalence of skin microfilariae 
decreased from 97.2% in 1992 to 57.0% in 2015 (a 41.4% 
reduction) but, more importantly, the CMFL decreased 
from 88.4  mf/ss to 1.6  mf/ss during the same period 
(98.2% reduction). This result supports the hypothesis 
that the impact of CDTI on the incidence of epilepsy is 
probably mainly due to a decrease in the quantitative 
indicators of transmission (CMFL and annual transmis-
sion potential in the vector population) and not in the 
skin microfilaria prevalence. This being said, a greater 
impact of CDTI on epilepsy would likely be achieved if 
drug coverage was higher in children. Unfortunately, 
another study conducted in the Bafia Health District 
showed that the coverage in 2014 was only 60% in chil-
dren aged 5–9 years, and that the values increased pro-
gressively with age [43].
A second limitation of our study is that other etiolo-
gies of epilepsy could not be fully accounted for, and it 
could be suspected, for instance, that improved maternal 
care has reduced perinatal brain damage in newborns. 
Nevertheless, to our knowledge, no large-scale inter-
vention against malaria is ongoing in the study area, 
other than the national bednet distribution programme. 
Notwithstanding these unaccounted factors, sensitivity 
analyses are reassuring on the consistency of our results, 
as data from the PWE or PE populations did not differ 
much from those from SCE.
Lastly, the definitions of suspect cases in 1991–1992 
and 2017 were close, but not strictly identical. The main 
reason is that the first survey was conducted before a 
validated questionnaire for identifying the SCE was avail-
able. In 2017 all declared SCE cases were considered 
whereas some were excluded by questioning in 1991–
1992, therefore marginally underestimating the initial 
SCE prevalences.
Interestingly, and independently from the principal 
objective of the study, we found a high positive predictive 
value of the 5-item questionnaire (88%) in our study area, 
that confirms its good screening accuracy [44]. Besides 
this, the analyses revealed the existence of a household 
effect, accounting for 23% of the variation in the risk of 
being a PWE. This can be explained by intrinsic genetic 
factors or by extrinsic factors shared by the household. 
The latter could be an intra-household similar intensity 
of exposure to blackfly bites, depending on the distance 
between the house or the workplace, and the river [45]. 
Figure 1 (right panel), suggests that in Nyamongo, like in 
other settings, there is a correlation between epilepsy and 
river proximity [19, 46].
Conclusions
In conclusion, our study adds to the growing body of evi-
dence for the impact of CDTI in decreasing the burden 
of epilepsy by limiting incident cases in hyperendemic 
onchocerciasis foci in Africa. Nevertheless, the still high 
epilepsy prevalence and the high prevalence of oncho-
cerciasis antibodies in children 7–10 years-old, indicates 
a need for advocacy to strengthen onchocerciasis elimi-
nation programmes and improve comprehensive health 
services for PWE in these rural areas.
Additional file
Additional file 1. Household questionnaire.
Abbreviations
CDTI: Community‑directed treatment with ivermectin; DRC: Democratic 
Republic of Congo; SCE: Suspected cases of epilepsy; PE: Possible epilepsy; 
PWE: Person with epilepsy; RDT: Rapid diagnostic rest; PY: Person‑years; AED: 
Antiepileptic drugs.
Acknowledgements
We are grateful to all the local authorities from Bayomen, Ngongol, and 
Nyamongo, as well as the population for their participation.
Page 12 of 13Boullé et al. Parasites Vectors          (2019) 12:114 
Funding
This research was funded by ERC Advanced Grant (671055), NSETHIO Project. 
The funders had no role in study design, data collection and analysis, decision 
to publish, or preparation of the manuscript.
Availability of data and materials
Data supporting the conclusions of this article are included within the article. 
The datasets used and/or analyzed during the present study are available from 
the corresponding author upon reasonable request.
Authors’ contributions
CB, AKN, FD, MKM and JNSF participated in the field study. AKN, ACKB, PS, 
HCND, JK, CBC, MB and RC designed the study. CB analyzed data. CB wrote the 
first manuscript draft. AKN, JNSF, ACKB, HCND, JK, CBC, MB and RC participated 
in the writing of the manuscript. All authors read and approved the final 
manuscript.
Ethics approval and consent to participate
The study protocol was approved by the ethical committee of the Univer‑
sity of Antwerp (registration number B300201731362) and the Cameroon 
National Ethics Committee for Research in Human Health (registration number 
2017/02/875/CE/CNERSH/SP). Administrative authorization to conduct the 
research was obtained from the Ministry of Public Health of Cameroon (D30‑
177/L/MINSANTE/SG/DROS/TMC). All adult participants provided written 
informed consent. A parent or guardian of any participant aged < 18 years 
provided written informed consent on their behalf, but child assent was 
systematically sought and recorded on a dedicated form for those aged 
12–18 years.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Author details
1 TransVIHMI, University of Montpellier, Inserm, IRD, Montpellier, France. 2 Infec‑
tious and Tropical Diseases Department, University Hospital, Nîmes, France. 
3 Neurology Department, Central Hospital of Yaoundé, Yaoundé, Cameroon. 
4 Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, 
Yaoundé, Cameroon. 5 Brain Research Africa Initiative (BRAIN), Yaoundé, 
Cameroon. 6 District Hospital of Yoko, Yoko, Cameroon. 7 Subdivisonal 
hospital of Mbangassina, Mbangassina, Cameroon. 8 Global Health Institute, 
University of Antwerp, Antwerp, Belgium. 9 Ministry of Public Health, Yaoundé, 
Cameroon. 10 Dermatology Department, Chantal Biya Mother‑Child Center, 
Yaoundé, Cameroon. 11 Centre for Research on Filariasis and other Tropical 
Diseases, Yaoundé, Cameroon. 
Received: 18 September 2018   Accepted: 26 February 2019
References
 1. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation 
of the burden of active and life‑time epilepsy: a meta‑analytic approach. 
Epilepsia. 2010;51:883–90.
 2. Newton CR, García HH. Epilepsy in poor regions of the world. Lancet. 
2012;380:1193–201.
 3. Ba‑Diop A, Marin B, Druet‑Cabanac M, Ngoungou EB, Newton CR, Preux 
PM. Epidemiology, causes, and treatment of epilepsy in sub‑Saharan 
Africa. Lancet Neurol. 2014;13:1029–44.
 4. Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton 
CR. Incidence of epilepsy: a systematic review and meta‑analysis. Neurol‑
ogy. 2011;10:1005–12.
 5. Debacq G, Moyano LM, García HH, Boumediene F, Marin B, Ngoungou 
EB, et al. Systematic review and meta‑analysis estimating association of 
cysticercosis and neurocysticercosis with epilepsy. PLoS Negl Trop Dis. 
2017;11:e0005153.
 6. Luna J, Cicero CE, Rateau G, Quattrocchi G, Marin B, Bruno E, et al. 
Updated evidence of the association between toxocariasis and 
epilepsy: systematic review and meta‑analysis. PLoS Negl Trop Dis. 
2018;12:e0006665.
 7. Ngoungou EB, Bhalla D, Nzoghe A, Dardé ML, Preux PM. Toxoplasmosis 
and epilepsy ‑ systematic review and meta analysis. PLoS Negl Trop Dis. 
2015;9:e0003525.
 8. Christensen SS, Eslick GD. Cerebral malaria as a risk factor for the develop‑
ment of epilepsy and other long‑term neurological conditions: a meta‑
analysis. Trans R Soc Trop Med Hyg. 2015;109:233–8.
 9. Casis Sacre G. El sindrome epileptico y su relacion con onchocercosis. Bol 
Salubr Hig. 1938;1:11–31.
 10. Druet‑Cabanac M, Boussinesq M, Dongmo L, Farnarier G, Bouteille B, 
Preux PM. Review of epidemiological studies searching for a relation‑
ship between onchocerciasis and epilepsy. Neuroepidemiology. 
2004;23:144–9.
 11. Pion SDS, Kaiser C, Boutros‑Toni F, Cournil A, Taylor MM, Meredith SEO, 
et al. Epilepsy in onchocerciasis endemic areas: systematic review 
and meta‑analysis of population‑based surveys. PLoS Negl Trop Dis. 
2009;3:e461.
 12. Kaiser C, Pion SDS, Boussinesq M. Case‑control studies on the relationship 
between onchocerciasis and epilepsy: systematic review and meta‑
analysis. PLoS Negl Trop Dis. 2013;7:e2147.
 13. Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, et al. Expo‑
sure to multiple parasites is associated with the prevalence of active con‑
vulsive epilepsy in sub‑Saharan Africa. PLoS Negl Trop Dis. 2014;8:e2908.
 14. Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza‑Mwesige A, 
Ae‑Ngibise K, et al. Prevalence of active convulsive epilepsy in sub‑Saha‑
ran Africa and associated risk factors: cross‑sectional and case‑control 
studies. Lancet Neurol. 2013;12:253–63.
 15. Levick B, Laudisoit A, Tepage F, Ensoy‑Musoro C, Mandro M, Bonareri 
Osoro C, et al. High prevalence of epilepsy in onchocerciasis endemic 
regions in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 
2017;11:e0005732.
 16. Colebunders R, Irani J, Post R. Nodding syndrome ‑ we can now prevent 
it. Int J Infect Dis. 2016;44:61–3.
 17. Spencer PS, Mazumder R, Palmer VS, Lasarev MR, Stadnik RC, King P, et al. 
Environmental, dietary and case‑control study of Nodding Syndrome 
in Uganda: a post‑measles brain disorder triggered by malnutrition? J 
Neurol Sci. 2016;369:191–203.
 18. Kipp W, Burnham G, Kamugisha J. Improvement in seizures after ivermec‑
tin. Lancet. 1992;340:789–90.
 19. Boussinesq M, Pion SDS, Demanga‑Ngangue, Kamgno J. Relationship 
between onchocerciasis and epilepsy: a matched case‑control study 
in the Mbam Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg. 
2002;96:537–41.
 20. Njamnshi AK, Yepnjio FN, Bissek ACZK, Tabah EN, Ongolo‑Zogo P, Dema F, 
et al. A survey of public knowledge, attitudes, and practices with respect 
to epilepsy in Badissa Village, Centre Region of Cameroon. Epilepsy 
Behav. 2009;16:254–9.
 21. Dongmo L, Druet‑Cabanac M, Moyou SR, Zebaze DRM, Njamnshi AK, Sini 
V, et al. Cysticercosis and epilepsy: a case‑control study in Mbam Valley, 
Cameroon. Bull Soc Pathol Exot. 2004;97:105–8.
 22. Ollivier G, Boussinesq M, Albaret JL, Cumberlidge N, Farhati K, Chippaux 
JP, et al. Epidemiological study of Paragonimus sp. in south Cameroon. 
Bull Soc Pathol Exot. 1995;88:164–9.
 23. Louis FJ, Louis‑Lutinier D. Le foyer historique de trypanosomiase de Bafia 
(Cameroun), objet de toutes les polémiques: revue bibliographique. Bull 
Liais Doc OCEAC. 1995;28:217–27.
 24. Preux PM. Questionnaire in a study of epilepsy in tropical countries. Bull 
Soc Pathol Exot. 2000;93:276–8.
 25. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. 
ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 
2014;55:475–82.
 26. Minnesota Population Center. Integrated Public Use Microdata Series, 
International: Version 7.0 [dataset]. Minneapolis, MN, USA: IPUMS; 2018. 
http://doi.org/10.18128 /D020.V70.
Page 13 of 13Boullé et al. Parasites Vectors          (2019) 12:114 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 27. Kamgno J, Pion SDS, Boussinesq M. Demographic impact of epilepsy 
in Africa: results of a 10‑year cohort study in a rural area of Cameroon. 
Epilepsia. 2003;44:956–63.
 28. World Health Organization. Report of the 1st meeting of the WHO 
onchocerciasis technical advisory subgroup, Varembé Conference Centre, 
Geneva, Switzerland, 10–12 October 2017. 2017. http://apps.who.int/iris/
bitst ream/handl e/10665 /27370 5/WHO‑CDS‑NTD‑PCT‑2018.05‑eng.pdf. 
Accessed 4 Nov 2017.
 29. Remme JHF, Zongo JB. Demographic aspects of the epidemiology and 
control of onchocerciasis in West Africa. In: Service M, editor. Demogra‑
phy and vector‑borne diseases. Boca Raton: CRC Press; 1989. p. 367–86.
 30. Kaiser C, Kipp W, Asaba G, Mugisa C, Kabagambe G. The prevalence of 
epilepsy follows the distribution of onchocerciasis in a west Ugandan 
focus. Bull World Health Organ. 1996;74:361.
 31. Osuntokun BO. Epidemiology of epilepsy in developing countries in 
Africa. Trop Geogr Med. 1978;30:23–32.
 32. Osuntokun BO, Adeuja AO, Nottidge VA, Bademosi O, Olumide A, Ige 
O, et al. Prevalence of the epilepsies in Nigerian Africans: a community‑
based study. Epilepsia. 1987;28:272–9.
 33. Diop AG, de Boer HM, Mandlhate C, Prilipko L, Meinardi H. The global 
campaign against epilepsy in Africa. Acta Trop. 2003;87:149–59.
 34. Newell ED, Vyungimana F, Bradley JE. Epilepsy, retarded growth and 
onchocerciasis, in two areas of different endemicity of onchocerciasis in 
Burundi. Trans R Soc Trop Med Hyg. 1997;91:525–7.
 35. König R, Nassri A, Meindl M, Matuja W, Kidunda AR, Siegmund V, et al. The 
role of Onchocerca volvulus in the development of epilepsy in a rural area 
of Tanzania. Parasitology. 2010;137:1559–68.
 36. Ovuga E, Kipp W, Mungherera M, Kasoro S. Epilepsy and retarded growth 
in a hyperendemic focus of onchocerciasis in rural western Uganda. East 
Afr Med J. 1992;69:554–6.
 37. Prischich F, De Rinaldis M, Bruno F, Egeo G, Santori C, Zappaterreno A, 
et al. High prevalence of epilepsy in a village in the Littoral Province of 
Cameroon. Epilepsy Res. 2008;82:200–10.
 38. Dozie INS, Onwuliri COE, Nwoke BEB, Chukwuocha UM, Chikwendu CI, 
Okoro I, et al. Onchocerciasis and epilepsy in parts of the Imo river basin, 
Nigeria: a preliminary report. Public Health. 2006;120:448–50.
 39. Chesnais CB, Nana‑Djeunga HC, Njamnshi AK, Lenou‑Nanga CG, Boullé 
C, Bissek AZ, et al. The temporal relationship between onchocercia‑
sis and epilepsy: a population‑based cohort study. Lancet Infect Dis. 
2018;11:1278–86.
 40. Mazzotti L. Presencia de microfilarias de Onchocerca volvulus en el líquido 
cefaloraquídeo de enfermos tratados con hetrazan. Rev Inst Salubr 
Enferm Trop. 1959;19:1–5.
 41. Duke BOL, Vincelette J, Moore PJ. Microfilariae in the cerebrospinal fluid, 
and neurological complications, during treatment of onchocerciasis with 
diethylcarbamazine. Tropenmed Parasitol. 1976;27:123–32.
 42. Kamga G‑R, Dissak‑Delon FN, Nana‑Djeunga HC, Biholong BD, Mbigha‑
Ghogomu S, Souopgui J, et al. Still mesoendemic onchocerciasis in two 
Cameroonian community‑directed treatment with ivermectin projects 
despite more than 15 years of mass treatment. Parasit Vectors. 2016;9:581.
 43. Kamga G‑R, Dissak‑Delon FN, Nana‑Djeunga HC, Biholong BD, Ghogomu 
SM, Souopgui J, et al. Audit of the community‑directed treatment with 
ivermectin (CDTI) for onchocerciasis and factors associated with adher‑
ence in three regions of Cameroon. Parasit Vectors. 2018;11:356.
 44. Diagana M, Preux PM, Tuillas M, Ould Hamady A, Druet‑Cabanac M. 
Dépistage de l’épilepsie en zones tropicales: validation d’un question‑
naire en Mauritanie. Bull Soc Pathol Exot. 2006;99:103–7.
 45. Cadot E, Barbazan P, Boussinesq M. Geographic determinants of oncho‑
cerciasis transmission in a forest‑savannah transition zone: an example 
of 2 villages of the Mbam focus (central region, Cameroon). Sante. 
1998;8:429–35.
 46. Colebunders R, Mandro M, Mokili JL, Mucinya G, Mambandu G, Pfarr K, 
et al. Risk factors for epilepsy in Bas‑Uélé Province, Democratic Republic 
of the Congo: a case‑control study. Int J Infect Dis. 2016;49:1–8.
